Careers  |  Sign In  |  Register

Latest in Oncology

Recent Developments in Next-Generation BRAF and MEK Inhibitors for Melanoma Treatment

Dr. Pavlick on the COLUMBUS Trial in Metastatic Melanoma

Anna C. Pavlick, DO, director of High Reliability Organization Initiatives and co-director of the Melanoma Program at NYU Langone Health’s Perlmutter Cancer Center, overviews next generation MEK and BRAF inhibitors used in the recently published phase 3 COLUMBUS trial for melanoma treatment. The COLUMBUS...
Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program - Clinical/Service at Emory University School of Medicine, Winship Cancer Institute, discusses how ocular melanoma and cutaneous...
In this interview, Ragini Kudchadkar, MD, associate professor in the Department of Hematology and Medical Oncology, and associate director of the Hematology and Medical Oncology Fellowship Program - Clinical/Service at Emory University School of Medicine, Winship Cancer Institute, discussed the prognosis...